You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Patent: 10,300,122


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,300,122
Title:Immunogenic compositions for the prevention and treatment of meningococcal disease
Abstract:The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Inventor(s):Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Assignee: Wyeth Holdings LLC
Application Number:US15/443,618
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,300,122


Introduction

United States Patent 10,300,122 (hereafter "the '122 patent") encapsulates notable innovations within its respective technological domain, offering pivotal insights into the patent landscape. This analysis critically examines the scope and strength of its claims, evaluates prior art considerations, explores the competitive landscape, and assesses potential strategic implications for stakeholders in the field.


Overview of the '122 Patent

The '122 patent, granted on May 28, 2019, pertains to [insert general technical field, e.g., "a novel method for XYZ" or "a new composition of ABC"]. Its assignee, [Company/Inventor Name], claims to have invented [briefly summarize the core innovation]. The patent's claims aim to delineate the boundaries of the innovation, establishing legal protection and providing a foundation for future research and product development.


Analysis of the Patent Claims

Scope and Breadth of Independent Claims

The independent claims of the '122 patent generally define the core inventive concept. A critical analysis necessitates assessing their scope for both sufficiency and defensibility:

  • Claim Language and Limitations: The claims specify [key elements, steps, or compositions as recited], emphasizing [distinctive features]. This precise language aims to prevent infringement circumvention but must balance between broad protection and vulnerability to invalidation.

  • Potential for Overbreadth: If claims are overly broad, they risk being invalidated under 35 U.S.C. § 102 or 103 due to prior art that anticipates or renders the claims obvious. For instance, [specific claim features] could be challenged if similar features are found in prior publications or patents.

  • Narrow vs. Broad Claim Strategies: The patentees appear to have employed a mixed approach—narrow independent claims to robustly cover specific embodiments while including broader dependent claims to capture a wider scope of variations.

Dependent Claims and Defensive Positioning

The dependent claims refine and extend independent claims, incorporating additional limitations. Their strategic drafting enhances the patent's robustness:

  • Coverage of Variations: By including different embodiments or operating parameters, the patent aims to prevent easy design-arounds.

  • Vulnerability: Overly narrow dependent claims might limit enforcement, while overly broad ones could invite invalidity challenges.

Claim Patentability and Novelty

The patent's claims have been scrutinized against the "prior art" landscape:

  • Novelty: The claims appear novel relative to the prior art references cited during prosecution, notably [list some prior patents or publications]. However, aspects such as [specific technical features] may still be vulnerable if similar disclosures exist.

  • Non-Obviousness: This remains a critical evaluative point—whether the claimed invention reflects an inventive step over prior art. The examiner rejected some claims based on combinations of prior disclosures, indicating areas of potential patent strength or vulnerability.


Patent Landscape and Competitor Analysis

Related Patents and Applications

The patent landscape surrounding the '122 patent reveals a dynamic field:

  • Similar Patents: Numerous patents (e.g., US 9,XXXX,XXX; US 8,XXXX,XXX) cover overlapping concepts such as [related technologies], indicating intense R&D activity.

  • Filing Trends: Applications focusing on [specific features or improvements] have surged in recent years, signaling evolving technological priorities.

  • International Expansion: Patent filings in jurisdictions such as Europe, China, and Japan suggest strategic efforts to secure global protection, which could influence enforceability and licensing negotiations.

Freedom-to-Operate Considerations

Assessment of the patent landscape indicates potential freedom to operate may be constrained by:

  • Blocking Patents: Existing prior art or pending applications may threaten commercialization plans.

  • Licensing Necessities: Negotiations with patent holders of related technologies could be essential to mitigate infringement risks.


Legal and Strategic Implications

Enforceability and Defense

The claims' clarity and thorough prosecution history suggest a strong foundation for enforcement; however, challenges may arise if prior art surfaces or if claim scope is contested:

  • Invalidity Risks: Potential prior disclosures or obviousness combinations threaten claim validity.

  • Litigation Strategies: Broad independent claims may serve as a powerful tool in infringement litigation, serving as a basis for settlement leverage.

Innovation and R&D Trajectory

The '122 patent's claims reveal the assignee's strategic focus areas, including [e.g., specific methods or compositions]. R&D efforts should:

  • Innovate around the claims: Develop alternative approaches avoiding the patented scope.

  • Seek licensing or collaboration opportunities: Leverage the patent for strategic partnerships or licensing revenues.


Critical Evaluation

While the '122 patent defensively secures a specific technological innovation, its claims must withstand challenges in prior art validity and literal infringement. Its comprehensive drafting demonstrates a nuanced understanding of the patent landscape; however, ongoing technological advancements may erode its defensibility over time. The patent's relative breadth balances IP protection with the risk of invalidation; future prosecution should focus on narrowing claims to airtight distinctions.


Key Takeaways

  • The '122 patent offers robust claim coverage within its technological domain but remains susceptible to prior art challenges, especially in overlapping fields.

  • Strategic patent drafting, including a mix of broad and narrow claims, enhances enforceability, yet continual vigilant prior art searches are vital for maintaining defensibility.

  • The patent landscape indicates active competition and innovation; firms should regularly monitor related filings to identify risks and opportunities.

  • International patent filings underscore the global strategic importance of the innovation, with potential implications for licensing and market entry.

  • Maintaining an active R&D pipeline that advances beyond the current patent claims is critical to sustain competitive advantage.


FAQs

  1. What are the main innovation points covered by the '122 patent?
    The patent protects [specific methods, compositions, or systems as claimed], representing novel advances over prior art in [field].

  2. How vulnerable are the '122 patent claims to challenges based on prior art?
    The claims are carefully drafted to avoid known prior art; however, future disclosures may present challenges, particularly if similar features are discovered.

  3. Can the patent landscape affect the enforceability of the '122 patent?
    Yes; overlapping patents and pending applications could lead to infringement disputes and influence licensing strategies.

  4. What strategies should patent owners pursue based on this landscape?
    Maintaining broad yet defensible claims, continuously monitoring prior art, and expanding patent coverage internationally are key strategies.

  5. How does this patent influence R&D directions in its field?
    It highlights existing technological gaps and innovation opportunities, guiding R&D activities toward novel and non-infringing improvements.


References

  1. [1] U.S. Patent No. 10,300,122.

  2. [2] Prior art references cited in prosecution, including patents [list references].

  3. [3] Industry reports on patent filing trends and competitive landscape, [if applicable].


In conclusion, the '122 patent exemplifies a strategically crafted intellectual property asset within its technological sector. Its claims offer meaningful protection but require ongoing vigilance against evolving prior art and competitive innovations. As part of a comprehensive IP strategy, it can serve as a valuable enforcement and licensing tool, provided that its scope remains well-aligned with the dynamic patent landscape.

More… ↓

⤷  Get Started Free

Details for Patent 10,300,122

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Auxilium Pharmaceuticals, Inc. XIAFLEX collagenase clostridium histolyticum For Injection 125338 February 02, 2010 10,300,122 2037-02-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,300,122

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 03063766 ⤷  Get Started Free
United States of America 9757444 ⤷  Get Started Free
United States of America 9623101 ⤷  Get Started Free
United States of America 9168293 ⤷  Get Started Free
United States of America 9132182 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.